190 related articles for article (PubMed ID: 35443321)
1. Clinical significance of the discrepancy between radiological findings and biochemical responses in atezolizumab plus bevacizumab for hepatocellular carcinoma.
Iwamoto H; Shimose S; Niizeki T; Koga H; Torimura T
Clin Mol Hepatol; 2022 Jul; 28(3):575-579. PubMed ID: 35443321
[No Abstract] [Full Text] [Related]
2. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial.
Galle PR; Finn RS; Qin S; Ikeda M; Zhu AX; Kim TY; Kudo M; Breder V; Merle P; Kaseb A; Li D; Mulla S; Verret W; Xu DZ; Hernandez S; Ding B; Liu J; Huang C; Lim HY; Cheng AL; Ducreux M
Lancet Oncol; 2021 Jul; 22(7):991-1001. PubMed ID: 34051880
[TBL] [Abstract][Full Text] [Related]
3. Letter to the editor: Atezolizumab plus bevacizumab for hepatocellular carcinoma in the real world.
Zhang J; Fang J; Xun Z; Xu Y; Lu X; Zhao H
Hepatology; 2022 Oct; 76(4):E84-E85. PubMed ID: 35604038
[No Abstract] [Full Text] [Related]
4. Current Role of Atezolizumab Plus Bevacizumab Therapy in the Sequential Treatment of Unresectable Hepatocellular Carcinoma.
Komatsu S; Yano Y; Fujishima Y; Ishida J; Kido M; Kuramitsu K; Yamamoto A; Goto T; Yanagimoto H; Toyama H; Ueda Y; Kodama Y; Fukumoto T
Anticancer Res; 2022 Mar; 42(3):1403-1412. PubMed ID: 35220233
[TBL] [Abstract][Full Text] [Related]
5. A Case of Pseudoprogression in Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab.
Watanabe Y; Ogawa M; Tamura Y; Suda S; Kaneko M; Kumagawa M; Hirayama M; Matsumoto N; Yamamoto T; Moriyama M
J Investig Med High Impact Case Rep; 2021; 9():23247096211058489. PubMed ID: 34845921
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib for Patients With Unresectable or Metastatic Hepatocellular Carcinoma.
Zhang X; Wang J; Shi J; Jia X; Dang S; Wang W
JAMA Netw Open; 2021 Apr; 4(4):e214846. PubMed ID: 33825837
[TBL] [Abstract][Full Text] [Related]
7. Atezolizumab and bevacizumab for non-resectable or metastatic combined hepatocellular-cholangiocarcinoma: A multicentric retrospective study.
Gigante E; Bouattour M; Bedoya JU; Regnault H; Ziol M; Assenat E; Paradis V; Calderaro J; Ganne-Carrié N; Bouhier-Leporrier K; Amaddeo G; Nault JC
United European Gastroenterol J; 2024 May; 12(4):429-439. PubMed ID: 38059651
[TBL] [Abstract][Full Text] [Related]
8. Liver dysfunction of Atezolizumab + Bevacizumab -a matter of life or death.
Obi S; Omata M
Liver Int; 2021 Jul; 41(7):1702-1703. PubMed ID: 34049421
[No Abstract] [Full Text] [Related]
9. Considering nutritional status to improve outcomes of patients treated by atezolizumab-bevacizumab for advanced hepatocellular carcinoma.
Allaire M; Avila MA
Liver Int; 2024 Jun; 44(6):1276-1277. PubMed ID: 38775365
[No Abstract] [Full Text] [Related]
10. [New approval: Atezolizumab and bevacizumab for first line of unresecable hepatocellular carcinoma].
Minot-This MS; Edeline J
Bull Cancer; 2021 Feb; 108(2):139-140. PubMed ID: 33546873
[No Abstract] [Full Text] [Related]
11. Atezolizumab plus Bevacizumab: A Novel Breakthrough in Hepatocellular Carcinoma.
Castet F; Willoughby CE; Haber PK; Llovet JM
Clin Cancer Res; 2021 Apr; 27(7):1827-1829. PubMed ID: 33472912
[TBL] [Abstract][Full Text] [Related]
12. Is ageing a problematic hurdle to the efficacy of first-line atezolizumab plus bevacizumab in hepatocellular carcinoma?
An J; Shim JH
Liver Int; 2022 Nov; 42(11):2352-2353. PubMed ID: 36162086
[No Abstract] [Full Text] [Related]
13. Atezolizumab plus bevacizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma: a cost-effectiveness analysis.
Hou Y; Wu B
Cancer Commun (Lond); 2020 Dec; 40(12):743-745. PubMed ID: 33159490
[No Abstract] [Full Text] [Related]
14. Synchronous Primary Lung Adenocarcinoma and Hepatocellular Carcinoma Successfully Treated with a Combination of Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel.
Egawa T; Masuzawa K; Nakayama S; Maeda I; Tsunematsu S; Suzuki Y; Suzuki Y
Intern Med; 2021 Oct; 60(20):3273-3277. PubMed ID: 33840693
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma.
Su D; Wu B; Shi L
JAMA Netw Open; 2021 Feb; 4(2):e210037. PubMed ID: 33625508
[TBL] [Abstract][Full Text] [Related]
16. Atezolizumab plus bevacizumab for advanced, unresectable hepatocellular carcinoma.
Tsilimigras DI; Moris D
J BUON; 2021; 26(2):637. PubMed ID: 34077021
[No Abstract] [Full Text] [Related]
17. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study.
Lee MS; Ryoo BY; Hsu CH; Numata K; Stein S; Verret W; Hack SP; Spahn J; Liu B; Abdullah H; Wang Y; He AR; Lee KH;
Lancet Oncol; 2020 Jun; 21(6):808-820. PubMed ID: 32502443
[TBL] [Abstract][Full Text] [Related]
18. Portal hypertension, advanced hepatocellular carcinoma and therapy by atezolizumab-bevacizumab: A "menage à trois" !
Campion B; Larrey E; Wagner M; Rudler M; Thabut D; Allaire M
Clin Res Hepatol Gastroenterol; 2022 Feb; 46(2):101785. PubMed ID: 34384926
[No Abstract] [Full Text] [Related]
19. Advanced hepatocellular carcinoma with response to lenvatinib after atezolizumab plus bevacizumab.
Yano S; Kawaoka T; Johira Y; Miura R; Kosaka M; Shirane Y; Murakami S; Amioka K; Naruto K; Ando Y; Kosaka Y; Yamaoka K; Kodama K; Uchikawa S; Fujino H; Ohno A; Nakahara T; Murakami E; Okamoto W; Yamauchi M; Imamura M; Mori K; Arihiro K; Kuroda S; Kobayashi T; Ohdan H; Aikata H
Medicine (Baltimore); 2021 Oct; 100(42):e27576. PubMed ID: 34678902
[TBL] [Abstract][Full Text] [Related]
20. Is Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma Superior Even to Lenvatinib? A Matching-Adjusted Indirect Comparison.
Casadei-Gardini A; Tada T; Shimose S; Kumada T; Niizeki T; Cascinu S; Cucchetti A
Target Oncol; 2021 Mar; 16(2):249-254. PubMed ID: 33638735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]